Johnni Rudbeck-Resdal

Johnni Rudbeck-Resdal

Auto-generated profile, based on publicly available information

Johnni Rudbeck-Resdal

Department of Cardiology Aarhus University Hospital Aarhus Denmark

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in EP Europace
Verified
Journal Article
Open access
PDF file
JRJohnni Rudbeck-Resdal
Johnni Rudbeck-Resdal
MCMorten K Christiansen
Morten K Christiansen
JJJens B Johansen
Jens B Johansen
JNJens C Nielsen
Jens C Nielsen
HBHenning Bundgaard
Henning Bundgaard
HJHenrik K Jensen
Henrik K Jensen
To describe aetiologies and temporal trends in young patients with atrioventricular block (AVB). We identified all patients in Denmark, receiving their first pacemaker because of AVB before the age of 50 years between 1996 and 2015. Medical records were reviewed and clinical information and diagnostic work-up results were obtained to evaluate the aetiology. We used Poisson regression testing for temporal trends. One thousand and twenty-seven patients were identified, median age at time of implantation was 38 (interquartile range 25–45) years, 584 (56.9%) were male. The aetiologies were complications to cardiac surgery [n = 157 (15.3%)], congenital AVB [n = 93 (9.0%)], cardioinhibitory reflex [n = 52 (5.0%)], congenital heart disease [n = 43 (4.2%)], complication to radiofrequency ablation [n = 35 (3.4%)], cardiomyopathy [n = 31 (3.0%)], endocarditis [n = 18 (1.7%)], muscular dystrophy [n = 14 (1.4%)], ischaemic heart disease [n = 14 (1.4%)], sarcoidosis [n = 11 (1.1%)], borreliosis [n = 9 (0.9%)], hereditary [n = 6 (0.6%)], side-effect to antiarrhythmics [n = 6 (0.6%)], planned His-ablation [n = 5 (0.5%)], complication to alcohol septal ablation [n = 5 (0.5%)], and other known aetiologies [n = 11 (1.1%)]. The aetiology remained unknown in 517 (50.3%) cases. While the number of patients with unknown aetiology increased during the study period (P < 0.001), we observed no significant change in the number of patients with identified aetiology (P = 0.35). In a nationwide cohort, the aetiology of AVB was identified in only half the patients younger than 50 years referred for first-time pacemaker implantation. The number of patients with unknown aetiology increased during the study period. These findings indicate need for better insight into aetiologies of AVB and improved diagnostic work-up guidelines.

18 February 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JDJohnni Resdal Dideriksen
Johnni Resdal Dideriksen
MCMorten K Christiansen
Morten K Christiansen
JJJens B Johansen
Jens B Johansen
JNJens C Nielsen
Jens C Nielsen
HBHenning Bundgaard
Henning Bundgaard
HJHenrik K Jensen
Henrik K Jensen
Atrioventricular block (AVB) of unknown aetiology is rare in the young, and outcome in these patients is unknown. We aimed to assess long-term morbidity and mortality in young patients with AVB of unknown aetiology. We identified all Danish patients younger than 50 years receiving a first pacemaker due to AVB between January 1996 and December 2015. By reviewing medical records, we included patients with AVB of unknown aetiology. A matched control cohort was established. Follow-up was performed using national registries. The primary outcome was a composite endpoint consisting of death, heart failure hospitalization, ventricular tachyarrhythmia, and cardiac arrest with successful resuscitation. We included 517 patients, and 5170 controls. Median age at first pacemaker implantation was 41.3 years [interquartile range (IQR) 32.7–46.2 years]. After a median follow-up of 9.8 years (IQR 5.7–14.5 years), the primary endpoint had occurred in 14.9% of patients and 3.2% of controls [hazard ratio (HR) 3.8; 95% confidence interval (CI) 2.9–5.1; P < 0.001]. Patients with persistent AVB at time of diagnosis had a higher risk of the primary endpoint (HR 10.6; 95% CI 5.7–20.0; P < 0.001), and risk was highest early in the follow-up period (HR 6.8; 95% CI 4.6–10.0; P < 0.001, during 0–5 years of follow-up). Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. Patients with persistent AVB were at higher risk. These findings warrant improved follow-up strategies for young patients with AVB of unknown aetiology. Atrioventricular block of unknown aetiology presenting before the age of 50 years and treated with pacemaker implantation was associated with a three- to four-fold higher rate of the composite endpoint of death or hospitalization for heart failure, ventricular tachyarrhythmia, or cardiac arrest with successful resuscitation. CI, confidence interval.

3 May 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JDJohnni Resdal Dyssekilde
Johnni Resdal Dyssekilde
TFTanja Charlotte Frederiksen
Tanja Charlotte Frederiksen
MCMorten Krogh Christiansen
Morten Krogh Christiansen
RSRikke Hasle Sørensen
Rikke Hasle Sørensen
LPLisbeth Nørum Pedersen
Lisbeth Nørum Pedersen
HJHenrik Kjærulf Jensen
Henrik Kjærulf Jensen
Background: The cause of atrioventricular block (AVB) remains unknown in approximately half of young patients with the diagnosis. Although variants in several genes associated with cardiac conduction diseases have been identified, the contribution of genetic variants in younger patients with AVB is unknown.Methods and Results: Using the Danish Pacemaker and Implantable Cardioverter Defibrillator (ICD) Registry, we identified all patients younger than 50 years receiving a pacemaker because of AVB in Denmark in the period from January 1, 1996 to December 31, 2015. From medical records, we identified patients with unknown cause of AVB at time of pacemaker implantation. These patients were invited to a genetic screening using a panel of 102 genes associated with inherited cardiac diseases. We identified 471 living patients with AVB of unknown cause, of whom 226 (48%) accepted participation. Median age at the time of pacemaker implantation was 39 years (interquartile range, 32–45 years), and 123 (54%) were men. We found pathogenic or likely pathogenic variants in genes associated with or possibly associated with AVB in 12 patients (5%). Most variants were found in theLMNAgene (n=5).LMNAvariant carriers all had a family history of either AVB and/or sudden cardiac death.Conclusions: In young patients with AVB of unknown cause, we found a possible genetic cause in 1 out of 20 participating patients. Variants in theLMNAgene were most common and associated with a family history of AVB and/or sudden cardiac death, suggesting that genetic testing should be a part of the diagnostic workup in these patients to stratify risk and screen family members.

1 March 2019 in HeartRhythm Case Reports
Verified
Journal Article
Open access
JRJohnni Rudbeck-Resdal
Johnni Rudbeck-Resdal
JNJens Cosedis Nielsen
Jens Cosedis Nielsen
HBHenning Bundgaard
Henning Bundgaard
HJHenrik K. Jensen
Henrik K. Jensen